Now showing items 1-8 of 8

    • 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. 

      Pan, H; Gray, R; Braybrooke, J; Davies, C; Taylor, C; McGale, P; Peto, R; Pritchard, KI; Bergh, J; Dowsett, M; Hayes, DF; EBCTCG (2017-11)
      Background The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such ...
    • Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. 

      Filipits, M; Dafni, U; Gnant, M; Polydoropoulou, V; Hills, M; Kiermaier, A; de Azambuja, E; Larsimont, D; Rojo, F; Viale, G; Toi, M; Harbeck, N; Prichard, KI; Gelber, RD; Dinh, P; Zardavas, D; Leyland-Jones, B; Piccart-Gebhart, MJ; Dowsett, M; TransHERA investigators (2018-07)
      Purpose: To assess the prognostic and predictive value of selected biomarkers involved in cell-cycle regulation or proliferation in patients with HER2-positive early breast cancer.Experimental Design: Protein expression ...
    • Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. 

      Abubakar, M; Chang-Claude, J; Ali, HR; Chatterjee, N; Coulson, P; Daley, F; Blows, F; Benitez, J; Milne, RL; Brenner, H; Stegmaier, C; Mannermaa, A; Rudolph, A; Sinn, P; Couch, FJ; Devilee, P; Tollenaar, RAEM; Seynaeve, C; Figueroa, J; Lissowska, J; Hewitt, S; Hooning, MJ; Hollestelle, A; Foekens, R; Koppert, LB; kConFab Investigators; Bolla, MK; Wang, Q; Jones, ME; Schoemaker, MJ; Keeman, R; Easton, DF; Swerdlow, AJ; Sherman, ME; Schmidt, MK; Pharoah, PD; Garcia-Closas, M (2018-08)
      Limited epidemiological evidence suggests that the etiology of hormone receptor positive (HR+) breast cancer may differ by levels of histologic grade and proliferation. We pooled risk factor and pathology data on 5,905 HR+ ...
    • Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. 

      Horne, HN; Chung, CC; Zhang, H; Yu, K; Prokunina-Olsson, L; Michailidou, K; Bolla, MK; Wang, Q; Dennis, J; Hopper, JL; Southey, MC; Schmidt, MK; Broeks, A; Muir, K; Lophatananon, A; Fasching, PA; Beckmann, MW; Fletcher, O; Johnson, N; Sawyer, EJ; Tomlinson, I; Burwinkel, B; Marme, F; Guénel, P; Truong, T; Bojesen, SE; Flyger, H; Benitez, J; González-Neira, A; Anton-Culver, H; Neuhausen, SL; Brenner, H; Arndt, V; Meindl, A; Schmutzler, RK; Brauch, H; Hamann, U; Nevanlinna, H; Khan, S; Matsuo, K; Iwata, H; Dörk, T; Bogdanova, NV; Lindblom, A; Margolin, S; Mannermaa, A; Kosma, V-M; Chenevix-Trench, G; kConFab/AOCS Investigators; Wu, AH; Ven den Berg, D; Smeets, A; Zhao, H; Chang-Claude, J; Rudolph, A; Radice, P; Barile, M; Couch, FJ; Vachon, C; Giles, GG; Milne, RL; Haiman, CA; Marchand, LL; Goldberg, MS; Teo, SH; Taib, NAM; Kristensen, V; Borresen-Dale, A-L; Zheng, W; Shrubsole, M; Winqvist, R; Jukkola-Vuorinen, A; Andrulis, IL; Knight, JA; Devilee, P; Seynaeve, C; García-Closas, M; Czene, K; Darabi, H; Hollestelle, A; Martens, JWM; Li, J; Lu, W; Shu, X-O; Cox, A; Cross, SS; Blot, W; Cai, Q; Shah, M; Luccarini, C; Baynes, C; Harrington, P; Kang, D; Choi, J-Y; Hartman, M; Chia, KS; Kabisch, M; Torres, D; Jakubowska, A; Lubinski, J; Sangrajrang, S; Brennan, P; Slager, S; Yannoukakos, D; Shen, C-Y; Hou, M-F; Swerdlow, A; Orr, N; Simard, J; Hall, P; Pharoah, PDP; Easton, DF; Chanock, SJ; Dunning, AM; Figueroa, JD (2016-01)
      The Cancer Genetic Markers of Susceptibility genome-wide association study (GWAS) originally identified a single nucleotide polymorphism (SNP) rs11249433 at 1p11.2 associated with breast cancer risk. To fine-map this locus, ...
    • Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. 

      Abubakar, M; Orr, N; Daley, F; Coulson, P; Ali, HR; Blows, F; Benitez, J; Milne, R; Brenner, H; Stegmaier, C; Mannermaa, A; Chang-Claude, J; Rudolph, A; Sinn, P; Couch, FJ; Devilee, P; Tollenaar, RAEM; Seynaeve, C; Figueroa, J; Sherman, ME; Lissowska, J; Hewitt, S; Eccles, D; Hooning, MJ; Hollestelle, A; Martens, JWM; van Deurzen, CHM; kConFab Investigators; Bolla, MK; Wang, Q; Jones, M; Schoemaker, M; Wesseling, J; van Leeuwen, FE; Van 't Veer, L; Easton, D; Swerdlow, AJ; Dowsett, M; Pharoah, PD; Schmidt, MK; Garcia-Closas, M (2016-10-18)
      Background The value of KI67 in breast cancer prognostication has been questioned due to concerns on the analytical validity of visual KI67 assessment and methodological limitations of published studies. Here, we investigate ...
    • Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. 

      Spurdle, AB; Couch, FJ; Parsons, MT; McGuffog, L; Barrowdale, D; Bolla, MK; Wang, Q; Healey, S; Schmutzler, R; Wappenschmidt, B; Rhiem, K; Hahnen, E; Engel, C; Meindl, A; Ditsch, N; Arnold, N; Plendl, H; Niederacher, D; Sutter, C; Wang-Gohrke, S; Steinemann, D; Preisler-Adams, S; Kast, K; Varon-Mateeva, R; Ellis, S; Frost, D; Platte, R; Perkins, J; Evans, DG; Izatt, L; Eeles, R; Adlard, J; Davidson, R; Cole, T; Scuvera, G; Manoukian, S; Bonanni, B; Mariette, F; Fortuzzi, S; Viel, A; Pasini, B; Papi, L; Varesco, L; Balleine, R; Nathanson, KL; Domchek, SM; Offitt, K; Jakubowska, A; Lindor, N; Thomassen, M; Jensen, UB; Rantala, J; Borg, Å; Andrulis, IL; Miron, A; Hansen, TVO; Caldes, T; Neuhausen, SL; Toland, AE; Nevanlinna, H; Montagna, M; Garber, J; Godwin, AK; Osorio, A; Factor, RE; Terry, MB; Rebbeck, TR; Karlan, BY; Southey, M; Rashid, MU; Tung, N; Pharoah, PDP; Blows, FM; Dunning, AM; Provenzano, E; Hall, P; Czene, K; Schmidt, MK; Broeks, A; Cornelissen, S; Verhoef, S; Fasching, PA; Beckmann, MW; Ekici, AB; Slamon, DJ; Bojesen, SE; Nordestgaard, BG; Nielsen, SF; Flyger, H; Chang-Claude, J; Flesch-Janys, D; Rudolph, A; Seibold, P; Aittomäki, K; Muranen, TA; Heikkilä, P; Blomqvist, C; Figueroa, J; Chanock, SJ; Brinton, L; Lissowska, J; Olson, JE; Pankratz, VS; John, EM; Whittemore, AS; West, DW; Hamann, U; Torres, D; Ulmer, HU; Rüdiger, T; Devilee, P; Tollenaar, RAEM; Seynaeve, C; Van Asperen, CJ; Eccles, DM; Tapper, WJ; Durcan, L; Jones, L; Peto, J; dos-Santos-Silva, I; Fletcher, O; Johnson, N; Dwek, M; Swann, R; Bane, AL; Glendon, G; Mulligan, AM; Giles, GG; Milne, RL; Baglietto, L; McLean, C; Carpenter, J; Clarke, C; Scott, R; Brauch, H; Brüning, T; Ko, Y-D; Cox, A; Cross, SS; Reed, MWR; Lubinski, J; Jaworska-Bieniek, K; Durda, K; Gronwald, J; Dörk, T; Bogdanova, N; Park-Simon, T-W; Hillemanns, P; Haiman, CA; Henderson, BE; Schumacher, F; Le Marchand, L; Burwinkel, B; Marme, F; Surovy, H; Yang, R; Anton-Culver, H; Ziogas, A; Hooning, MJ; Collée, JM; Martens, JWM; Tilanus-Linthorst, MMA; Brenner, H; Dieffenbach, AK; Arndt, V; Stegmaier, C; Winqvist, R; Pylkäs, K; Jukkola-Vuorinen, A; Grip, M; Lindblom, A; Margolin, S; Joseph, V; Robson, M; Rau-Murthy, R; González-Neira, A; Arias, JI; Zamora, P; Benítez, J; Mannermaa, A; Kataja, V; Kosma, V-M; Hartikainen, JM; Peterlongo, P; Zaffaroni, D; Barile, M; Capra, F; Radice, P; Teo, SH; Easton, DF; Antoniou, AC; Chenevix-Trench, G; Goldgar, DE; ABCTB Investigators; EMBRACE Group; GENICA Network; HEBON Group; kConFab Investigators (2014-12-23)
      Introduction The distribution of histopathological features of invasive breast tumors in BRCA1 or BRCA2 germline mutation carriers differs from that of individuals with no known mutation. Histopathological features thus ...
    • The Intracranial Distribution of Gliomas in Relation to Exposure From Mobile Phones: Analyses From the INTERPHONE Study. 

      Grell, K; Frederiksen, K; Schüz, J; Cardis, E; Armstrong, B; Siemiatycki, J; Krewski, DR; McBride, ML; Johansen, C; Auvinen, A; Hours, M; Blettner, M; Sadetzki, S; Lagorio, S; Yamaguchi, N; Woodward, A; Tynes, T; Feychting, M; Fleming, SJ; Swerdlow, AJ; Andersen, PK (2016-12)
      When investigating the association between brain tumors and use of mobile telephones, accurate data on tumor position are essential, due to the highly localized absorption of energy in the human brain from the radio-frequency ...
    • Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study. 

      Buus, R; Sestak, I; Barron, S; Loughman, T; Fender, B; Ruiz, CL; Dynoodt, P; Wang, C-JA; O'Leary, D; Gallagher, WM; Dowsett, M; Cuzick, J (2020-02)
      Purpose To test the validity of OncoMasTR Molecular Score (OMm), OMclin1, and OncoMasTR Risk Score (OMclin2) prognostic scores for prediction of distant recurrence (DR) in estrogen receptor (ER)-positive/HER2-negative ...